@book{16604, author = {Sepúlveda Sánchez, Juan Manuel and Servicio de Oncología Médica}, title = {Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. }, publisher = {Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,}, year = {2014}, note = {Formato Vancouver: Balañá C, Vaz MA, López D, de la Peñas R, García Bueno JM, Molina Garrido MJ et al. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. Clin Transl Oncol. 2014 Mar;16(3):273-9. }, url = {http://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16604.pdf} }